144 related articles for article (PubMed ID: 15767337)
1. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans.
Rudolph RE; Dominitz JA; Lampe JW; Levy L; Qu P; Li SS; Lampe PD; Bronner MP; Potter JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):605-8. PubMed ID: 15767337
[TBL] [Abstract][Full Text] [Related]
2. Increased frequency of serrated aberrant crypt foci among smokers.
Anderson JC; Pleau DC; Rajan TV; Protiva P; Swede H; Brenner B; Heinen CD; Lambrecht RW; Rosenberg DW
Am J Gastroenterol; 2010 Jul; 105(7):1648-54. PubMed ID: 20234347
[TBL] [Abstract][Full Text] [Related]
3. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
4. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
5. Association of visceral fat accumulation and plasma adiponectin with rectal dysplastic aberrant crypt foci in a clinical population.
Takahashi H; Takayama T; Yoneda K; Endo H; Iida H; Sugiyama M; Fujita K; Yoneda M; Inamori M; Abe Y; Saito S; Wada K; Nakagama H; Nakajima A
Cancer Sci; 2009 Jan; 100(1):29-32. PubMed ID: 19018760
[TBL] [Abstract][Full Text] [Related]
6. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
8. Aberrant crypt focus size predicts distal polyp histopathology.
Kim J; Ng J; Arozulllah A; Ewing R; Llor X; Carroll RE; Benya RV
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1155-62. PubMed ID: 18483337
[TBL] [Abstract][Full Text] [Related]
9. Aberrant crypt foci: what we know and what we need to know.
Gupta AK; Pretlow TP; Schoen RE
Clin Gastroenterol Hepatol; 2007 May; 5(5):526-33. PubMed ID: 17433788
[TBL] [Abstract][Full Text] [Related]
10. The natural history of aberrant crypt foci.
Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
[TBL] [Abstract][Full Text] [Related]
11. Aberrant crypt foci of the colon as precursors of adenoma and cancer.
Takayama T; Katsuki S; Takahashi Y; Ohi M; Nojiri S; Sakamaki S; Kato J; Kogawa K; Miyake H; Niitsu Y
N Engl J Med; 1998 Oct; 339(18):1277-84. PubMed ID: 9791143
[TBL] [Abstract][Full Text] [Related]
12. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas.
Martin C; Connelly A; Keku TO; Mountcastle SB; Galanko J; Woosley JT; Schliebe B; Lund PK; Sandler RS
Gastroenterology; 2002 Dec; 123(6):1770-7. PubMed ID: 12454832
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
15. Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence.
Uchiyama T; Takahashi H; Endo H; Kato S; Sakai E; Hosono K; Yoneda M; Inamori M; Hippo Y; Nakagama H; Nakajima A
Dig Endosc; 2012 Sep; 24(5):353-7. PubMed ID: 22925289
[TBL] [Abstract][Full Text] [Related]
16. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer.
Stevens RG; Swede H; Heinen CD; Jablonski M; Grupka M; Ross B; Parente M; Tirnauer JS; Giardina C; Rajan TV; Rosenberg DW; Levine J
Cancer Lett; 2007 Apr; 248(2):262-8. PubMed ID: 16950561
[TBL] [Abstract][Full Text] [Related]
17. Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.
Ohkubo H; Takahashi H; Yamada E; Sakai E; Higurashi T; Uchiyama T; Hosono K; Endo H; Taguri M; Nakajima A
Oncol Rep; 2012 May; 27(5):1475-80. PubMed ID: 22246586
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance, apoptosis, and colorectal adenoma risk.
Keku TO; Lund PK; Galanko J; Simmons JG; Woosley JT; Sandler RS
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2076-81. PubMed ID: 16172212
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic changes in aberrant crypt foci and serrated polyps.
Suehiro Y; Hinoda Y
Cancer Sci; 2008 Jun; 99(6):1071-6. PubMed ID: 18384435
[TBL] [Abstract][Full Text] [Related]
20. Association between cigarette smoking and colorectal cancer in the Women's Health Initiative.
Paskett ED; Reeves KW; Rohan TE; Allison MA; Williams CD; Messina CR; Whitlock E; Sato A; Hunt JR
J Natl Cancer Inst; 2007 Nov; 99(22):1729-35. PubMed ID: 18000222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
